In this episode, Dr. Veltmeyer explains his own specific protocol for administering the JadiCell stem cell treatment to patients. The Veltmeyer Protocol involves first detoxifying the body of elements which can hinder the successful transmission of the stem cells into the body. Once detoxified, the patient is ready to receive the JadiCell infusion.
Stem cell therapy is the future of medicine. However, why is it not revolutionizing medicine right now?
Let me explain.
Currently, the majority of medical interventions for chronic or degenerative diseases are based on treatment of symptoms. Stem cell therapy is a revolutionary type of medicine because it is based on regeneration of injured or aged tissues, thereby fixing the actual cause of the disease.
Although numerous clinical trials have demonstrated that adult stem cells are safe to administer, full demonstration of efficacy has not been achieved in large clinical trials. The reason for this is because conventional stem cell protocols provide the stem cells to patients without preparing the body for administration of the cells.
In many degenerative conditions, the underlying disease processes change the body such that when cells enter the body their therapeutic activity is minimized. This is because of various toxic agents which make the target tissue inhospitable for the stem cells.
The Veltmeyer Protocol involves utilization of various interventions before injection of stem cells such that the disease-induced elements which make the body hostile to stem cells are minimized.
According to the Veltmeyer Protocol, blood levels of these toxic agents associated with reduction of stem cell viability and activity are measured before stem cell therapy. Patients are placed on disease and patient specific interventions. Only when the patient’s body is ready to receive the stem cells because it has properly been detoxified, only then, are the stem cells administered. The problem is that when one administers stem cells but the body is full of toxicities, it becomes just like planting seeds on gravel…they just do not have a chance to function or to grow.
So let us give you one example of the Veltmeyer Protocol in action.
Take patients with heart failure. Many of them have high levels of inflammatory markers such as CRP, TNF-alpha. Some of them also have sleep apnea which is not treated, as well as an altered microbiome ( microbial environment ) characterized by dysbiosis ( a medical condition caused by microbial imbalances within the body ) and reduced alpha diversity index. In these patients, administration of stem cells intravenously usually results in the stem cells sticking to blood vessels all over the body…the stem cells being “consumed” by the inflammation, and the various factors made by the altered microbiome blocking the few stem cells left from exerting any type of therapeutic activity.
For this type of patient, upon intake we proceed to understand the various pathologies that are associated with his heart failure and address them. Once there is a sufficient reduction in all of these co-factors, then we administer stem cells. After stem cell administration, we continue the “detoxification” procedure and also assess regenerative potential through our proprietary test. In this way, we derive the optimum value of stem cell therapy.
It should be noted that T-regulatory cells are the body’s unique defense mechanism against inflammation. The importance of these cells is seen most profoundly in patients with a genetic disease called IPEX who lack T-regulatory cells. Patients with this condition have multiple autoimmune diseases.
In patients with neurodegenerative diseases such as ALS ( Amyotrophic lateral sclerosis ), there is a correlation between survival and the number of T-regulatory cells that can actually produce nerve protective growth factors. In animal studies, direct administration of T-regulatory cells have been associated with disease remission or cure. Unfortunately, to date there is no easy way to generate patient specific T-regulatory cells. Therefore, we are extremely optimistic at our ability to naturally stimulate increases in T-regulatory cells through providing stem cells to our patients.
In the case of an ALS patient cited in a prior commentary, the improvement of her T-regulatory cells after stem cell therapy has been astounding, up from 47% to 77% post-JadiCell infusion treatment. Another case is that of a 5 1/2 year old boy diagnosed with autism who has literally not spoken a single word since birth. After JadiCell infusion, he is now actually talking for the first time in his life!
Of course, every individual is different and, obviously, results and progress will differ from person to person. Some individuals may need treatment for a short period of time and others perhaps for the rest of their lives. And, the treatment is not inexpensive and is normally not covered by health insurance. One of the main objectives of the Veltmeyer Institute of Advanced Biologics is to make stem cell therapy affordable and accessible to the vast majority of people needing such treatment. If we can reach this goal, we will have made another gigantic stride toward healing people of some of the most destructive diseases to plague mankind.